- Home
- CHN vs INBX Comparison
CHN vs INBX Comparison
Compare CHN & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHN
- INBX
- Stock Information
- Founded
- CHN 1992
- INBX 2010
- Country
- CHN United States
- INBX United States
- Employees
- CHN N/A
- INBX N/A
- Industry
- CHN Investment Managers
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- CHN Finance
- INBX Health Care
- Exchange
- CHN Nasdaq
- INBX Nasdaq
- Market Cap
- CHN 153.9M
- INBX 178.5M
- IPO Year
- CHN N/A
- INBX 2020
- Fundamental
- Price
- CHN $15.87
- INBX $21.06
- Analyst Decision
- CHN
- INBX Hold
- Analyst Count
- CHN 0
- INBX 1
- Target Price
- CHN N/A
- INBX N/A
- AVG Volume (30 Days)
- CHN 31.8K
- INBX 109.7K
- Earning Date
- CHN 01-01-0001
- INBX 08-19-2025
- Dividend Yield
- CHN 0.19%
- INBX N/A
- EPS Growth
- CHN N/A
- INBX N/A
- EPS
- CHN N/A
- INBX 111.58
- Revenue
- CHN N/A
- INBX $200,000.00
- Revenue This Year
- CHN N/A
- INBX N/A
- Revenue Next Year
- CHN N/A
- INBX N/A
- P/E Ratio
- CHN N/A
- INBX $0.19
- Revenue Growth
- CHN N/A
- INBX N/A
- 52 Week Low
- CHN $9.00
- INBX $10.80
- 52 Week High
- CHN $12.98
- INBX $25.29
- Technical
- Relative Strength Index (RSI)
- CHN 64.58
- INBX 50.75
- Support Level
- CHN $15.40
- INBX $20.76
- Resistance Level
- CHN $16.06
- INBX $23.03
- Average True Range (ATR)
- CHN 0.20
- INBX 1.69
- MACD
- CHN -0.07
- INBX -0.57
- Stochastic Oscillator
- CHN 46.53
- INBX 10.76
About CHN China Fund Inc. (The)
CHINA FUND INC is a non-diversified, closed-end management investment company. Its investment objective is a long-term capital appreciation which it seeks to achieve by investing in equity securities with trading in China and outside China. It invests in various industries such as Insurance, Entertainment, Machinery, Electrical Equipment, Beverages, Hotels, Restaurants, and Leisure among others.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.